Skip to main content

Table 3 Ongoing phase III trials with targeted agents in advanced gastric cancer

From: Targeted and novel therapy in advanced gastric cancer

Targeted pathway

Agent/selection biomarker

Trial design

ClinicalTrials.gov identifier

HER

Varlitinib/HER1 and HER2

Phase II/III 1st-line comparing varlitinib plus mFOLFOX6 versus placebo plus mFOLFOX6

NCT03130790

Nimotuzumab/HER1

ENRICH 2nd-line comparing irinotecan with or without nimotuzumab in Asian patients

NCT01813253

Angiogenesis

Ramucirumab/HER2(−)

ARMANI comparing maintenance therapy with ramucirumab plus paclitaxel versus continuation of 1st-line chemotherapy

NCT02934464

Regorafenib/none

INTEGRATEII 3rd-line comparing regorafenib versus placebo

NCT02773524

Apatinib/none

ANGEL 3rd-line comparing apatinib versus placebo

NCT03042611

Fruquintinib/none

FRUTIGA 2nd-line comparing fruquintinib plus paclitaxel versus placebo plus paclitaxel 

NCT03223376

Anlotinib/none

ALTER0503 3rd-line comparing anlotinib versus placebo

NCT02461407

PD-1/PD-L1

Nivolumab with or without ipilimumab/HER2(−)

CheckMate649 1st-line comparing nivolumab plus ipilimumab or nivolumab plus chemotherapy against chemotherapy alone

NCT02872116

Nivolumab/HER2(−)

ATTRACTION-4 1st-line comparing nivolumab plus chemotherapy versus placebo plus chemotherapy

NCT02746796

Pembrolizumab/PD-L1

KEYNOTE-063 2nd-line comparing pembrolizumab versus paclitaxel in Asian patients

NCT03019588

Pembrolizumab/HER2

KEYNOTE-811 1st-line comparing pembrolizumab plus trastuzumab in combination with chemotherapy versus placebo plus trastuzumab in combination with chemotherapy

NCT03615326

Pembrolizumab/none

KEYNOTE-590 1st-line in esophageal including gastroesophageal junction cancer comparing chemotherapy versus chemotherapy plus pembrolizumab in Chinese patients

NCT03189719

Avelumab/HER2(−)

JAVELIN Gastric 100 comparing maintenance therapy with avelumab versus continuation of 1st-line chemotherapy

NCT02625610

FGFR2

FPA144/FGFR2 & HER2(−)

FIGHT/1st-line comparing FPA144 plus mFOLFOX6 versus placebo plus mFOLFOX6

NCT03694522

Claudin 18.2

IMAB362/claudin 18.2 & HER2(−)

SPOTLIGHT/1st-line comparing IMAB362 plus mFOLFOX6 versus placebo plus mFOLFOX6

NCT03504397

  1. HER human epidermal growth factor receptor, mFOLFOX6 5-fluorouracil/leucovorin/oxaliplatin, PD-1 programmed death-1, PD-L1 programmed death ligand 1, FGFR2 fibroblast growth factor receptor 2